@DocRirie @FZores La littérature est discordante a ce sujet. Il y a des études qui montrent un possible bénéfice, mais la Cochrane dit non : https://t.co/KYXePOdaCf
RT @Cochrane_DE: Die Autor*innen dieses #CochraneReview wollten wissen, ob blutverdünnende Medikamente wie Aspirin eine Verschlechterung vo…
Die Autor*innen dieses #CochraneReview wollten wissen, ob blutverdünnende Medikamente wie Aspirin eine Verschlechterung von Gedächtnis und Denkvermögen verhindern können, die bei Erkrankungen der kleinen Hirngefäße auftritt. https://t.co/1krRWKDtLB https:/
RT @PratiqueAvancee: Traitement antithrombotique dans la prévention du déclin cognitif chez les personnes présentant une maladie des petits…
Traitement antithrombotique dans la prévention du déclin cognitif chez les personnes présentant une maladie des petits vaisseaux sur la neuro-imagerie mais sans démence ➡️pas de données probantes convaincantes suggérant un bénéfice cognitif @CochraneFrance
RT @CochraneJapan: 神経画像上で脳小血管病を有するが認知症でない人の認知機能低下予防のための抗血栓療法 https://t.co/g5bUwntQIj
神経画像上で脳小血管病を有するが認知症でない人の認知機能低下予防のための抗血栓療法 https://t.co/g5bUwntQIj
RT @CochraneDCIG: "Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without deme…
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia https://t.co/WPEro4a1nU
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
New article: Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia https://t.co/g30ydZcQug #alzheimers #neurology https://t.co/NPqU8QMdjz
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
@Daniel_Magos
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
Was anyone prescribing ASA for white matter disease? Preventative neurology folks, thoughts? #NeuroTwitter
RT @CochraneDCIG: "Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without deme…
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
RT @CochraneDCIG: "Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without deme…
RT @drjkwan: BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of us…
BREAKING: Our new Cochrane review: no evidence of clinically relevant cognitive benefit of antithrombotic therapy on top of usual Rx for cerebral small vessel disease but without dementia (but may ⬆️ bleed risk) @DrTerryQuinn @StrokeImperial @CochraneDCIG
"Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia" review published https://t.co/g8Nx75Ynmq #Cochrane #evidencesynthesis #SysRev #systematicreview #CDCIG https://t.co/ZSaa92s7qv